PhaseBio Pharmaceuticals Inc

2020 Q1 Form 10-K Financial Statement

#000116924520000043 Filed on March 30, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2018 Q4 2018

Balance Sheet

Concept 2020 Q1 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.40M $61.00M $61.03M
YoY Change 14.45% 355.11%
Cash & Equivalents $59.40M $61.03M $61.03M
Short-Term Investments
Other Short-Term Assets $12.20M $1.300M $1.360M
YoY Change 713.33% 300.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables $896.0K $233.0K
Total Short-Term Assets $72.54M $62.63M $62.63M
YoY Change 34.15% 354.95% 355.49%
LONG-TERM ASSETS
Property, Plant & Equipment $2.637M $355.0K $360.0K
YoY Change 593.95% 17.55% 20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $32.00K $43.00K $40.00K
YoY Change 0.0% 38.71% -20.0%
Total Long-Term Assets $4.317M $398.0K $400.0K
YoY Change 86.8% 19.52% 14.29%
TOTAL ASSETS
Total Short-Term Assets $72.54M $62.63M $62.63M
Total Long-Term Assets $4.317M $398.0K $400.0K
Total Assets $76.86M $63.03M $63.03M
YoY Change 36.31% 347.02% 347.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.918M $1.806M $1.810M
YoY Change -8.67% 320.0% 320.93%
Accrued Expenses $1.900M $2.771M $2.770M
YoY Change 46.15% 116.32% 116.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $3.686M $0.00 $0.00
YoY Change 821.5% -100.0% -100.0%
Total Short-Term Liabilities $7.495M $4.577M $4.580M
YoY Change 97.24% -73.99% -73.98%
LONG-TERM LIABILITIES
Long-Term Debt $11.06M $7.500M $7.500M
YoY Change 61.64% 185.71% 75.23%
Other Long-Term Liabilities $295.0K $0.00 $20.00K
YoY Change -82.65% 100.0%
Total Long-Term Liabilities $11.35M $7.500M $7.520M
YoY Change 65.96% 185.71% 75.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.495M $4.577M $4.580M
Total Long-Term Liabilities $11.35M $7.500M $7.520M
Total Liabilities $23.37M $12.10M $12.10M
YoY Change 89.95% -44.71% -44.7%
SHAREHOLDERS EQUITY
Retained Earnings -$177.1M -$122.9M
YoY Change 35.99% 24.07%
Common Stock $29.00K $25.00K
YoY Change 16.0% 2400.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $24.00K $24.00K
YoY Change 0.0% 0.0%
Treasury Stock Shares 29.97K shares 29.97K shares
Shareholders Equity $53.49M $50.93M $50.93M
YoY Change
Total Liabilities & Shareholders Equity $76.86M $63.03M $63.03M
YoY Change 36.31% 347.02% 347.02%

Cashflow Statement

Concept 2020 Q1 2018 Q4 2018

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001169245
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28780640 shares
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
254700000 USD
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2018 phas Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
95000 USD
CY2019 phas Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
0 USD
CY2018Q4 phas Accrued Clinical And Related Costs Current
AccruedClinicalAndRelatedCostsCurrent
1358000 USD
CY2019Q4 phas Accrued Clinical And Related Costs Current
AccruedClinicalAndRelatedCostsCurrent
819000 USD
CY2018 phas Accrued Interest On Term Loan Refinanced To Principal
AccruedInterestOnTermLoanRefinancedToPrincipal
0 USD
CY2019 phas Accrued Interest On Term Loan Refinanced To Principal
AccruedInterestOnTermLoanRefinancedToPrincipal
308000 USD
CY2019 phas Aggregate Offering Price Of Common Stock Preferred Stock Debt Securities And Warrants
AggregateOfferingPriceOfCommonStockPreferredStockDebtSecuritiesAndWarrants
200000000 USD
CY2018 phas Conversion Of Redeemable Convertible Preferred Stock Into Common Stock
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock
125609000 USD
CY2018 phas Conversion Of Redeemable Convertible Preferred Stock Warrants Into Common Stock Warrants
ConversionOfRedeemableConvertiblePreferredStockWarrantsIntoCommonStockWarrants
3346000 USD
CY2019 phas Conversion Of Redeemable Convertible Preferred Stock Into Common Stock
ConversionOfRedeemableConvertiblePreferredStockIntoCommonStock
0 USD
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Registrant Name
EntityRegistrantName
PhaseBio Pharmaceuticals Inc
CY2019 phas Conversion Of Redeemable Convertible Preferred Stock Warrants Into Common Stock Warrants
ConversionOfRedeemableConvertiblePreferredStockWarrantsIntoCommonStockWarrants
0 USD
CY2018 phas Debt Refinanced With New Term Loan
DebtRefinancedWithNewTermLoan
0 USD
CY2019 phas Debt Refinanced With New Term Loan
DebtRefinancedWithNewTermLoan
6563000 USD
CY2018 phas Deferred Stock Offering Costs In Accounts Payable
DeferredStockOfferingCostsInAccountsPayable
0 USD
CY2019 phas Deferred Stock Offering Costs In Accounts Payable
DeferredStockOfferingCostsInAccountsPayable
110000 USD
CY2018Q4 phas Deferred Tax Assets Gross Before Valuation Allowance
DeferredTaxAssetsGrossBeforeValuationAllowance
36796000 USD
CY2019Q4 phas Deferred Tax Assets Gross Before Valuation Allowance
DeferredTaxAssetsGrossBeforeValuationAllowance
49975000 USD
CY2019Q4 phas Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
545000 USD
CY2019Q4 phas Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
527000 USD
CY2018 phas Effective Income Tax Rate Reconciliation Change In State Rate Amount
EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount
0 USD
CY2019 phas Effective Income Tax Rate Reconciliation Change In State Rate Amount
EffectiveIncomeTaxRateReconciliationChangeInStateRateAmount
34000 USD
CY2018 phas Income Tax Reconciliation Fair Value Adjustments
IncomeTaxReconciliationFairValueAdjustments
-15000 USD
CY2019 phas Income Tax Reconciliation Fair Value Adjustments
IncomeTaxReconciliationFairValueAdjustments
0 USD
CY2018 phas Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
706000 USD
CY2019 phas Income Tax Reconciliation Nondeductible Expense Interest
IncomeTaxReconciliationNondeductibleExpenseInterest
0 USD
CY2018 phas Income Tax Reconciliation Of Permanent Items
IncomeTaxReconciliationOfPermanentItems
3000 USD
CY2019 phas Income Tax Reconciliation Of Permanent Items
IncomeTaxReconciliationOfPermanentItems
16000 USD
CY2018 phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
17000 USD
CY2019 phas Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
37000 USD
CY2019 phas Net Operating Losses And Tax Credit Carryforwards Limitations On Change In Ownership Minimum Percentage
NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnChangeInOwnershipMinimumPercentage
0.50
CY2019 phas Net Operating Losses And Tax Credit Carryforwards Limitations On Change In Ownership Period
NetOperatingLossesAndTaxCreditCarryforwardsLimitationsOnChangeInOwnershipPeriod
P3Y
CY2019 phas Right Of Use Asset And Lease Liabilities Recorded Upon Adoption Of Asc842
RightOfUseAssetAndLeaseLiabilitiesRecordedUponAdoptionOfASC842
1991000 USD
CY2018 phas Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
-69000 USD
CY2018 phas Unrecognized Tax Benefits Expiration
UnrecognizedTaxBenefitsExpiration
0 USD
CY2019 phas Unrecognized Tax Benefits Expiration
UnrecognizedTaxBenefitsExpiration
0 USD
CY2018 phas Warrant Liability Converted To Redeemable Convertible Preferred Stock Upon Exercise Of Warrants
WarrantLiabilityConvertedToRedeemableConvertiblePreferredStockUponExerciseOfWarrants
4297000 USD
CY2019 phas Warrant Liability Converted To Redeemable Convertible Preferred Stock Upon Exercise Of Warrants
WarrantLiabilityConvertedToRedeemableConvertiblePreferredStockUponExerciseOfWarrants
0 USD
CY2019Q4 phas Working Capital
WorkingCapital
70300000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1806000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2921000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2771000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3180000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1785000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1959000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
173837000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
222131000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock
95000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
332000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1421000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
355000 USD
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
332000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1421000 USD
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1621000 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2727313 shares
CY2018Q4 us-gaap Assets
Assets
63026000 USD
CY2019Q4 us-gaap Assets
Assets
82494000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
62628000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
78823000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61031000 USD
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
39000 USD
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
823000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
25000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
29000 USD
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24498275 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28766404 shares
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74025000 USD
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13426000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61051000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74025000 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
47625000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12974000 USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24528242 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28796371 shares
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
2822000 USD
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
355000 USD
CY2018 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
19778000 USD
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
18000 USD
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
555000 USD
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
22000 USD
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
69000 USD
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
60000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
36814000 USD
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50530000 USD
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31744000 USD
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
42872000 USD
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
54000 USD
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
322000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
4615000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
6212000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
332000 USD
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
519000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36800000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
36796000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
50000000 USD
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49975000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
18000 USD
CY2019Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
28000 USD
CY2019 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000 USD
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
105000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4857000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11186000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23800000 USD
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-39200000 USD
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
174000 USD
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13179000 USD
CY2018 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-15000 USD
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.49
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.43
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
914000 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1746000 USD
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-11000 USD
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 USD
CY2019 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-17000 USD
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
6426000 USD
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
0 USD
CY2018 us-gaap Income Tax Reconciliation Deductions Medicare Prescription Drug Benefit Subsidy
IncomeTaxReconciliationDeductionsMedicarePrescriptionDrugBenefitSubsidy
475000 USD
CY2019 us-gaap Income Tax Reconciliation Deductions Medicare Prescription Drug Benefit Subsidy
IncomeTaxReconciliationDeductionsMedicarePrescriptionDrugBenefitSubsidy
925000 USD
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-5008000 USD
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8242000 USD
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
45000 USD
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
56000 USD
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-52000 USD
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-52000 USD
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1593000 USD
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-3783000 USD
CY2018 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
222000 USD
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
548000 USD
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
274000 USD
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
763000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1337000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
802000 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1923000 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-327000 USD
CY2018 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
233000 USD
CY2019 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
1000000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1017000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1954000 USD
CY2018 us-gaap Interest Expense
InterestExpense
3924000 USD
CY2019 us-gaap Interest Expense
InterestExpense
1076000 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
260000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
576000 USD
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
194000 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
84000 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
1582000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
272000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
22516000 USD
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
387000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
363000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
377000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
387000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
278000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2160000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
498000 USD
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
372000 USD
CY2018Q1 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
P3Y
CY2018Q4 us-gaap Liabilities
Liabilities
12099000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
63026000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82494000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4577000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8479000 USD
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2378000 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
7500000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
12326000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
64797000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53528000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-119000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-960000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17053000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39594000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-23846000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-39247000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
20312000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
42097000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-19644000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-39736000 USD
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
500000 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1773000 USD
CY2018Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
265000 USD
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1508000 USD
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1715000 USD
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.064
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y1M6D
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
305000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
266000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
43000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4202000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
489000 USD
CY2018Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
233000 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
1233000 USD
CY2018 us-gaap Paid In Kind Interest
PaidInKindInterest
3664000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
32000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
203000 USD
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
500000 USD
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
145000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
119000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
960000 USD
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Units Offering Costs
PreferredUnitsOfferingCosts
200000000.0 USD
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1344000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3565000 USD
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
42974000 USD
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
46277000 USD
CY2018 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
3995000 USD
CY2019 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
8089000 USD
CY2018 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
17712000 USD
CY2019 us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
0 USD
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
92000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
245000 USD
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24000 USD
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2018 us-gaap Profit Loss
ProfitLoss
-23846000 USD
CY2019 us-gaap Profit Loss
ProfitLoss
-39247000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2140000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3883000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
355000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1924000 USD
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
938000 USD
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15455000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30911000 USD
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000 USD
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
20000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162200000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-162158000 USD
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-122911000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
668000 USD
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2361000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
332000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1421000 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 USD
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.75
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.62
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
125609000 USD
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42974000 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
46277000 USD
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
92000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
245000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-97416000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
50927000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
59978000 USD
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
29967 shares
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
29967 shares
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
24000 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
24000 USD
CY2018 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-676000 USD
CY2019 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1293000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1809000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1800000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2560000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2600000 USD
CY2018 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
362000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
645000 USD
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
154000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
106000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-6400000 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13200000 USD
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5305062 shares
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27493558 shares
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:8px;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains certain deposits in federally insured financial institutions in excess of federally insured limits. The Company could experience losses on the money market funds in the future.</font></div></div>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The preparation of the Company&#8217;s financial statements requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s financial statements and accompanying notes. The most significant estimates in the Company&#8217;s financial statements relate to the valuation of redeemable convertible preferred stock warrants prior to the Initial Public Offering ("IPO"), the conversion option on the convertible notes and clinical trial accruals. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</font></div></div>

Files In Submission

Name View Source Status
0001169245-20-000043-index-headers.html Edgar Link pending
0001169245-20-000043-index.html Edgar Link pending
0001169245-20-000043.txt Edgar Link pending
0001169245-20-000043-xbrl.zip Edgar Link pending
a10-k2019.htm Edgar Link pending
ex1013-10xk2019.htm Edgar Link pending
ex1016-10xk2019.htm Edgar Link pending
ex1017-10xk2019.htm Edgar Link pending
ex1018-10xk2019.htm Edgar Link pending
ex1021-10xk2019.htm Edgar Link pending
ex1022-10xk2019.htm Edgar Link pending
ex1023-10xk2019.htm Edgar Link pending
ex231-10xk2019.htm Edgar Link pending
ex311-10xk2019.htm Edgar Link pending
ex312-10xk2019.htm Edgar Link pending
ex321-10xk2019.htm Edgar Link pending
ex322-10xk2019.htm Edgar Link pending
ex410-10xk2019.htm Edgar Link pending
ex411-10xk2019.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gssxylni2hvz000002a02.jpg Edgar Link pending
gssxylni2hvz000003a02.jpg Edgar Link pending
gssxylni2hvz000004a02.jpg Edgar Link pending
gssxylni2hvz000005a02.jpg Edgar Link pending
gssxylni2hvz000006a02.jpg Edgar Link pending
phas-20191231.xml Edgar Link completed
phas-20191231.xsd Edgar Link pending
phas-20191231_cal.xml Edgar Link unprocessable
phas-20191231_def.xml Edgar Link unprocessable
phas-20191231_lab.xml Edgar Link unprocessable
phas-20191231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slide1a03.jpg Edgar Link pending